Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challenges
Identifieur interne : 001B34 ( Main/Curation ); précédent : 001B33; suivant : 001B35Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challenges
Auteurs : Regina Katzenschlager [Royaume-Uni, Autriche] ; Andrew Hughes [Australie] ; Andrew Evans [Royaume-Uni] ; Alice J. Manson [Royaume-Uni] ; Marion Hoffman [Australie] ; Lesley Swinn [Royaume-Uni] ; Hilary Watt [Royaume-Uni] ; Kailash Bhatia [Royaume-Uni] ; Niall Quinn [Royaume-Uni] ; Andrew J. Lees [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-02.
English descriptors
- KwdEn :
Abstract
Continuous subcutaneous (SC) infusion of the dopamine agonist apomorphine was shown in retrospective studies to improve drug‐induced dyskinesias in Parkinson's disease (PD). We prospectively assessed the antidyskinetic effect of continuous SC apomorphine therapy using subjective and objective measures, and sought to determine whether any observed dyskinesia reduction could be corroborated using single‐dose dopaminergic challenges. Twelve PD patients with on–off fluctuations and disabling dyskinesias who were scheduled to start apomorphine pump treatment underwent acute levodopa and apomorphine challenges at baseline and 6 months later. Video recordings involving motor tasks were rated blindly by two independent raters using modified AIMS and Goetz dyskinesia scales. At 6 months, mean apomorphine dose was 75.2 mg per day and the mean l‐dopa dose had been reduced by 55%. Daily off time in patients' diaries was reduced by 38% (2.4 hours). The l‐dopa challenges showed a reduction of 44% in AIMS and 40% in Goetz scores (both P < 0.01). Apomorphine challenges showed a reduction of 39% in AIMS and 36% in Goetz scores (both P < 0.01). Patients' self‐assessment scores reflected these significant changes. Dyskinesia improvement correlated with reduction in oral medication and with the final apomorphine dose (P < 0.05). This prospective study confirms marked dyskinesia reduction on continuous subcutaneous apomorphine therapy, paralleled by reduced dyskinesias during dopaminergic challenge tests. Our findings support the concept that replacement of short‐acting oral antiparkinsonian medication with continuous dopamine receptor stimulation may reverse, at least partially, the sensitization process believed to mediate the development of drug‐induced dyskinesias in PD. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20276
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001E20
Links to Exploration step
ISTEX:AE01024FDA3247AD150ADF611980FB0A10BB27E3Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challenges</title><author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name><affiliation wicri:level="1"><mods:affiliation>Reta Lila Weston Institute of Neurological Studies, University College London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, University College London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Donauspital/Sozialmedizinisches Zentrum‐Ost, Vienna, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, Donauspital/Sozialmedizinisches Zentrum‐Ost, Vienna</wicri:regionArea></affiliation></author><author><name sortKey="Hughes, Andrew" sort="Hughes, Andrew" uniqKey="Hughes A" first="Andrew" last="Hughes">Andrew Hughes</name><affiliation wicri:level="1"><mods:affiliation>Austin and Repatriation Medical Centre, West Heidelberg, Victoria, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Austin and Repatriation Medical Centre, West Heidelberg, Victoria</wicri:regionArea></affiliation></author><author><name sortKey="Evans, Andrew" sort="Evans, Andrew" uniqKey="Evans A" first="Andrew" last="Evans">Andrew Evans</name><affiliation wicri:level="1"><mods:affiliation>Reta Lila Weston Institute of Neurological Studies, University College London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, University College London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea></affiliation></author><author><name sortKey="Manson, Alice J" sort="Manson, Alice J" uniqKey="Manson A" first="Alice J." last="Manson">Alice J. Manson</name><affiliation wicri:level="1"><mods:affiliation>Wessex Neurological Centre, Southampton, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Wessex Neurological Centre, Southampton</wicri:regionArea></affiliation></author><author><name sortKey="Hoffman, Marion" sort="Hoffman, Marion" uniqKey="Hoffman M" first="Marion" last="Hoffman">Marion Hoffman</name><affiliation wicri:level="1"><mods:affiliation>Austin and Repatriation Medical Centre, West Heidelberg, Victoria, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Austin and Repatriation Medical Centre, West Heidelberg, Victoria</wicri:regionArea></affiliation></author><author><name sortKey="Swinn, Lesley" sort="Swinn, Lesley" uniqKey="Swinn L" first="Lesley" last="Swinn">Lesley Swinn</name><affiliation wicri:level="1"><mods:affiliation>The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea></affiliation></author><author><name sortKey="Watt, Hilary" sort="Watt, Hilary" uniqKey="Watt H" first="Hilary" last="Watt">Hilary Watt</name><affiliation wicri:level="1"><mods:affiliation>Medical Statistics Unit, London School of Hygiene and Tropical Medicine and Institute of Neurology, Queen Square, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Medical Statistics Unit, London School of Hygiene and Tropical Medicine and Institute of Neurology, Queen Square, London</wicri:regionArea></affiliation></author><author><name sortKey="Bhatia, Kailash" sort="Bhatia, Kailash" uniqKey="Bhatia K" first="Kailash" last="Bhatia">Kailash Bhatia</name><affiliation wicri:level="1"><mods:affiliation>Sobell Department of Motor Neurosciences and Movement Disorders, Institute of Neurology, University College London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Sobell Department of Motor Neurosciences and Movement Disorders, Institute of Neurology, University College London</wicri:regionArea></affiliation></author><author><name sortKey="Quinn, Niall" sort="Quinn, Niall" uniqKey="Quinn N" first="Niall" last="Quinn">Niall Quinn</name><affiliation wicri:level="1"><mods:affiliation>Sobell Department of Motor Neurosciences and Movement Disorders, Institute of Neurology, University College London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Sobell Department of Motor Neurosciences and Movement Disorders, Institute of Neurology, University College London</wicri:regionArea></affiliation></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name><affiliation wicri:level="1"><mods:affiliation>Reta Lila Weston Institute of Neurological Studies, University College London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, University College London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:AE01024FDA3247AD150ADF611980FB0A10BB27E3</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20276</idno><idno type="url">https://api.istex.fr/document/AE01024FDA3247AD150ADF611980FB0A10BB27E3/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001E20</idno><idno type="wicri:Area/Main/Curation">001B34</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challenges</title><author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name><affiliation wicri:level="1"><mods:affiliation>Reta Lila Weston Institute of Neurological Studies, University College London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, University College London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Donauspital/Sozialmedizinisches Zentrum‐Ost, Vienna, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, Donauspital/Sozialmedizinisches Zentrum‐Ost, Vienna</wicri:regionArea></affiliation></author><author><name sortKey="Hughes, Andrew" sort="Hughes, Andrew" uniqKey="Hughes A" first="Andrew" last="Hughes">Andrew Hughes</name><affiliation wicri:level="1"><mods:affiliation>Austin and Repatriation Medical Centre, West Heidelberg, Victoria, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Austin and Repatriation Medical Centre, West Heidelberg, Victoria</wicri:regionArea></affiliation></author><author><name sortKey="Evans, Andrew" sort="Evans, Andrew" uniqKey="Evans A" first="Andrew" last="Evans">Andrew Evans</name><affiliation wicri:level="1"><mods:affiliation>Reta Lila Weston Institute of Neurological Studies, University College London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, University College London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea></affiliation></author><author><name sortKey="Manson, Alice J" sort="Manson, Alice J" uniqKey="Manson A" first="Alice J." last="Manson">Alice J. Manson</name><affiliation wicri:level="1"><mods:affiliation>Wessex Neurological Centre, Southampton, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Wessex Neurological Centre, Southampton</wicri:regionArea></affiliation></author><author><name sortKey="Hoffman, Marion" sort="Hoffman, Marion" uniqKey="Hoffman M" first="Marion" last="Hoffman">Marion Hoffman</name><affiliation wicri:level="1"><mods:affiliation>Austin and Repatriation Medical Centre, West Heidelberg, Victoria, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Austin and Repatriation Medical Centre, West Heidelberg, Victoria</wicri:regionArea></affiliation></author><author><name sortKey="Swinn, Lesley" sort="Swinn, Lesley" uniqKey="Swinn L" first="Lesley" last="Swinn">Lesley Swinn</name><affiliation wicri:level="1"><mods:affiliation>The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea></affiliation></author><author><name sortKey="Watt, Hilary" sort="Watt, Hilary" uniqKey="Watt H" first="Hilary" last="Watt">Hilary Watt</name><affiliation wicri:level="1"><mods:affiliation>Medical Statistics Unit, London School of Hygiene and Tropical Medicine and Institute of Neurology, Queen Square, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Medical Statistics Unit, London School of Hygiene and Tropical Medicine and Institute of Neurology, Queen Square, London</wicri:regionArea></affiliation></author><author><name sortKey="Bhatia, Kailash" sort="Bhatia, Kailash" uniqKey="Bhatia K" first="Kailash" last="Bhatia">Kailash Bhatia</name><affiliation wicri:level="1"><mods:affiliation>Sobell Department of Motor Neurosciences and Movement Disorders, Institute of Neurology, University College London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Sobell Department of Motor Neurosciences and Movement Disorders, Institute of Neurology, University College London</wicri:regionArea></affiliation></author><author><name sortKey="Quinn, Niall" sort="Quinn, Niall" uniqKey="Quinn N" first="Niall" last="Quinn">Niall Quinn</name><affiliation wicri:level="1"><mods:affiliation>Sobell Department of Motor Neurosciences and Movement Disorders, Institute of Neurology, University College London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Sobell Department of Motor Neurosciences and Movement Disorders, Institute of Neurology, University College London</wicri:regionArea></affiliation></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name><affiliation wicri:level="1"><mods:affiliation>Reta Lila Weston Institute of Neurological Studies, University College London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, University College London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-02">2005-02</date><biblScope unit="volume">20</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="151">151</biblScope><biblScope unit="page" to="157">157</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">AE01024FDA3247AD150ADF611980FB0A10BB27E3</idno><idno type="DOI">10.1002/mds.20276</idno><idno type="ArticleID">MDS20276</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>apomorphine</term><term>dyskinesias</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Continuous subcutaneous (SC) infusion of the dopamine agonist apomorphine was shown in retrospective studies to improve drug‐induced dyskinesias in Parkinson's disease (PD). We prospectively assessed the antidyskinetic effect of continuous SC apomorphine therapy using subjective and objective measures, and sought to determine whether any observed dyskinesia reduction could be corroborated using single‐dose dopaminergic challenges. Twelve PD patients with on–off fluctuations and disabling dyskinesias who were scheduled to start apomorphine pump treatment underwent acute levodopa and apomorphine challenges at baseline and 6 months later. Video recordings involving motor tasks were rated blindly by two independent raters using modified AIMS and Goetz dyskinesia scales. At 6 months, mean apomorphine dose was 75.2 mg per day and the mean l‐dopa dose had been reduced by 55%. Daily off time in patients' diaries was reduced by 38% (2.4 hours). The l‐dopa challenges showed a reduction of 44% in AIMS and 40% in Goetz scores (both P < 0.01). Apomorphine challenges showed a reduction of 39% in AIMS and 36% in Goetz scores (both P < 0.01). Patients' self‐assessment scores reflected these significant changes. Dyskinesia improvement correlated with reduction in oral medication and with the final apomorphine dose (P < 0.05). This prospective study confirms marked dyskinesia reduction on continuous subcutaneous apomorphine therapy, paralleled by reduced dyskinesias during dopaminergic challenge tests. Our findings support the concept that replacement of short‐acting oral antiparkinsonian medication with continuous dopamine receptor stimulation may reverse, at least partially, the sensitization process believed to mediate the development of drug‐induced dyskinesias in PD. © 2004 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B34 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001B34 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Curation
|type= RBID
|clé= ISTEX:AE01024FDA3247AD150ADF611980FB0A10BB27E3
|texte= Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challenges
}}
| This area was generated with Dilib version V0.6.23. |  |